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Abstract:  SUMMARY 
The ability to proliferate independently of signals from other cell types is a fundamental characteristic of 
tumor cells. Using a 3D culture model of human breast cancer progression, we have delineated a protease-
dependent autocrine loop which provides an oncogenic stimulus in the absence of proto-oncogene mutation. 
Inhibition of this protease, TACE/ADAM17, reverts the malignant phenotype by preventing mobilization of 
two crucial growth factors, Amphiregulin and TGFα. We show further that the efficacy of EGFR inhibitors is 
overcome by physiological levels of growth factors and that successful EGFR inhibition is dependent on 
reducing ligand bioavailability. Using existing patient outcome data, we demonstrate a strong correlation 
between TACE and TGFα expression in human breast cancers that is predictive of poor prognosis.  
 
SIGNIFICANCE 
Tumors resulting from inappropriate activation of the EGFR are common in multiple tissues and are, for the 
most part, refractory to current targeted therapies. The data presented here delineate the molecular 
mechanism by which constitutive EGFR activity may be achieved in tumor progression without mutation of 
the EGFR or downstream pathway components. These data implicate TACE as a therapeutically tractable 
enzyme, the inhibition of which effectively blocks EGFR signaling by preventing mobilization of ligands for 
this receptor. The data provide mechanistic insight into the insensitivity of EGFR-overexpressing tumors to 
anilinoquinazoline inhibitors and suggest that co-ordinate inhibition of TACE might augment the activity of 
EGFR inhibitors in a clinical setting. 
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the online submission system.   
 
The enclosed work was presented briefly by me during my talk on the first night, and in a poster 
by my postdoctoral fellow, Paraic Kenny, and received considerable attention.  I had mentioned 
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consideration 
 
The work details our recent investigations into the mechanistic basis which underlies activation 
of the EGFR in a 3D culture model of human breast cancer progression. In this model, as in the 
vast majority of breast cancers, common proto-oncogenes such as Ras and Raf are not mutated. 
We have delineated an autocrine loop, necessary for proliferation, in which malignant cells 
upregulate the expression of two growth factors, TGFα and Amphiregulin. We have 
demonstrated that the function of these growth factors is dependent upon cleavage by a co-
expressed transmembrane protease, TACE/ADAM17. Importantly, we show that inhibition of 
TACE (using either small molecules or siRNA) blocks mobilization of these growth factors 
resulting in the restoration of the non-malignant mammary acinar phenotype in these malignant 
cells in the 3D culture assay (restoration of apicobasal polarity and growth arrest). This is a 
direct phenocopy of EGFR inhibition.  Given the surprisingly disappointing result of the clinical 
trials with EGFR inhibitors (see below), our results provide a possible explanation: The data 
suggest an entirely new way of targeting the EGFR in tumors of the breast and possibly other 
epithelial tissues.  
 
To show that our results indeed are directly relevant to cancer in vivo, we did an extensive 
analysis of a publicly available microarray dataset consisting of expression profiles and 
associated clinical outcomes of 295 breast cancer patients (van de Vijver et al. NEJM, 347, 
1999-2009 (2002). We show that expression of both TGFα and TACE is predictive of poor 
prognosis in this patient population.  
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Summary  
The ability to proliferate independently of signals from other cell types is a fundamental 
characteristic of tumor cells. Using a 3D culture model of human breast cancer 
progression, we have delineated a protease-dependent autocrine loop which provides an 
oncogenic stimulus in the absence of proto-oncogene mutation. Inhibition of this 
protease, TACE/ADAM17, reverts the malignant phenotype by preventing mobilization 
of two crucial growth factors, Amphiregulin and TGFα. We show further that the 
efficacy of EGFR inhibitors is overcome by physiological levels of growth factors and 
that successful EGFR inhibition is dependent on reducing ligand bioavailability. Using 
existing patient outcome data, we demonstrate a strong correlation between TACE and 
TGFα expression in human breast cancers that is predictive of poor prognosis.  
 
Significance  
Tumors resulting from inappropriate activation of the EGFR are common in multiple 
tissues and are, for the most part, refractory to current targeted therapies. The data 
presented here delineate the molecular mechanism by which constitutive EGFR activity 
may be achieved in tumor progression without mutation of the EGFR or downstream 
pathway components. These data implicate TACE as a therapeutically tractable enzyme, 
the inhibition of which effectively blocks EGFR signaling by preventing mobilization of 
ligands for this receptor. The data provide mechanistic insight into the insensitivity of 
EGFR-overexpressing tumors to anilinoquinazoline inhibitors and suggest that co-
ordinate inhibition of TACE might augment the activity of EGFR inhibitors in a clinical 
setting. 
 
Introduction 
Whether achieved by gene overexpression, mutation, or amplification, the ability 
to grow independently of signals from other cell types is a central feature of 
tumorigenesis, and the acquisition of self-sufficiency for growth signals is a critical rate-
limiting transition in the evolution of a tumor cell (Hanahan and Weinberg, 2000). 
Pathways downstream of the Epidermal Growth Factor Receptor (EGFR) play essential 
roles in cell proliferation. Genetic ablation of this receptor or of certain ligands impairs 
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mammary gland development (Luetteke et al., 1999; Wiesen et al., 1999), while 
deregulated ErbB pathway signaling contributes to a significant proportion of human 
cancer cases, both in the breast and in other tissues (Downward, 2003). Thus, appropriate 
spatial and temporal regulation of EGFR signaling is crucial for correct mammary gland 
development and for the maintenance of mammary epithelial organization.  
We have used three-dimensional (3D) culture models of breast epithelial cells to 
investigate the molecular determinants of constitutive growth factor receptor signaling 
and to evaluate the phenotypic consequences of targeting these processes. The HMT3522 
breast cancer progression series originated from purified human breast epithelial cells 
derived from reduction mammoplasty (Briand et al., 1987). Early passages (S1) are 
spontaneously immortalized, non-malignant cells which require exogenous EGF for 
proliferation (Briand et al., 1987) and retain the capacity to differentiate into growth-
arrested, polarized acinar structures with central lumina when cultured in 3D gels of 
extracellular matrix (Petersen et al., 1992). Later passages (T4-2) grow independently of 
exogenous EGF and are tumorigenic in vivo (Briand et al., 1996). They fail to arrest 
growth in the 3D assay and form large, continuously proliferating apolar colonies. As 
these cells are ERα-negative and EGFR/ERBB2-positive, they are representative of a 
class of breast tumors with poor prognosis (Slamon et al., 1987; Sommer and Fuqua, 
2001). Treatment of T4-2 cells in 3D culture with inhibitors of components of the EGFR 
pathway elicits a striking morphological reversion of this malignant behavior and the 
assumption of an organized, growth-arrested, polarized acinar structure (Wang et al., 
1998).  
Here, we use this model to investigate the mechanisms by which non-malignant 
breast epithelial cells may escape dependence on exogenous EGF. A dissection of the 
EGFR pathway in T4-2 cells revealed that these cells lack mutations in common proto-
oncogenes (H-Ras, K-Ras, N-Ras and B-Raf) but express two EGFR ligands not present 
in S1 cells, Amphiregulin (AREG) and TGFα. A metalloproteinase activity, 
TACE/ADAM17, implicated by others in processing of these ligands (Borrell-Pages et 
al., 2003; Gschwind et al., 2003; Sahin et al., 2004), is expressed in T4-2 cells and is 
necessary for AREG and TGFα function. We show that inhibition of TACE is sufficient 
to block EGFR signaling and to revert the malignant phenotype in T4-2 cells and that this 
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is a direct consequence of attenuation of growth factor ectodomain shedding. Analysis of 
a published microarray dataset encompassing 295 primary breast tumors and associated 
clinical data (van de Vijver et al., 2002) revealed that TACE and TGFα expression are 
highly correlated and predictive of a poor prognosis. 
 These data provide further insight into this fundamental feature of tumorigenesis 
in the breast and other epithelial tissues and suggest that targeting this ADAM-dependent 
autocrine loop may prove an entirely new therapeutic strategy for EGFR-dependent 
tumors. In this regard, we have recognized the lack of success of EGFR inhibitors in 
recent phase III clinical trials (Giaccone et al., 2004; Herbst et al., 2004) and have 
hypothesized that availability of ligands may counter the efficacy of these drugs. We 
show that the reversion of malignancy induced by EGFR inhibition is overcome by low 
picomolar quantities of EGFR ligands – concentrations within the normal physiological 
range of these proteins. These data suggest that approaches which limit EGFR ligand 
bioavailability (such as TACE inhibition) might augment the effect of EGFR inhibitors in 
a clinical setting. 
 
Results 
Amphiregulin and TGFα are upregulated in T4-2 cells 
S1 non-malignant human breast epithelial cells require exogenous EGF for 
proliferation (Figure 1B,C), while their malignant derivatives, T4-2, have acquired self-
sufficiency for this signal. The sensitivity of T4-2 cells to inhibition of EGFR (Wang et 
al., 1998) implies that EGFR and the downstream components of the pathway are not 
mutationally activated. Using direct sequencing, we showed that these cells have not 
sustained activating mutations in H-Ras, K-Ras, N-Ras or B-Raf (data not shown). Thus, 
we hypothesized that T4-2 cells escaped dependence on exogenous EGF by 
transcriptionally upregulating one or more ErbB ligands. We tested expression of 
Amphiregulin, Betacellulin, Cripto, EGF, Epiregulin, HB-EGF, NRG1, NRG2 and 
TGFα by RT-PCR. Amphiregulin and TGFα were expressed at high levels in T4-2 cells 
(Figure 1A). Experiments using concentrations of recombinant AREG or 
TGFα equimolar to that of EGF (860 pM) show that these ligands can substitute for EGF 
to promote proliferation of the non-malignant cells (Figure 1D-F). 
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By the time an incipient cancer cell has become malignant, it is characterized by 
multiple genomic mutations, chromosomal amplifications and deletions, and aneuploidy 
(Albertson et al., 2003; Rajagopalan et al., 2003). In such a chaotic background, it is 
often difficult to distinguish between causative changes, correlative changes and changes 
of little consequence. If the changes we have observed in expression of these genes in 
malignant T4-2 cells are indeed important, one might expect that some of them would be 
detected at earlier stages of progression. On the continuum between S1 and T4-2 cells, a 
subline was established which, like S1 cells, is non-malignant but which grows 
independently of EGF and has lost the ability to form growth-arrested polarized acinar 
structures in 3D lrECM culture. This subline, S2 cells, was derived from S1 cells by EGF 
withdrawal after 118 passages (Briand et al., 1996). Analysis of the expression of AREG 
and TGFα in S2 cells (Figure 1G) demonstrates that both of these factors were 
upregulated during the transition from S1 to S2, the earliest stage of progression toward 
malignancy in this series.  
A metalloproteinase activity is critically required for mobilization of growth factors  
Several growth factors, including AREG and TGFα, are synthesized as 
transmembrane precursors and members of the ADAM family of transmembrane 
proteases have been implicated in the processing of these ligands (Borrell-Pages et al., 
2003; Gschwind et al., 2003; Sahin et al., 2004). Culture of T4-2 cells in 3D extracellular 
matrix results in the formation of disorganized, apolar, continuously proliferating 
colonies (Figure 2A), a phenotype we have shown to be highly correlated with, and 
reflective of, cancer cell malignancy (Petersen et al., 1992; Wang et al., 2002). Incubation 
with TAPI-2, a broad-spectrum inhibitor of MMPs and ADAMs, resulted in a reversion 
of the malignant phenotype (Figure 2C) similar to that elicited using the EGFR inhibitor 
AG1478 (Figure 2B), suggesting that a metalloproteinase activity is required for the 
proliferative phenotype of T4-2 cells. This treatment also resulted in the restoration of 
epithelial polarity. Vehicle-treated cells remained disorganized (Figure 2D) while TAPI-2 
treated cells assumed a polar organization similar to that of a breast acinus, here indicated 
by basal localization of α6-integrin (Figure 2E). The colonies formed by AG1478 or 
TAPI-2 treated T4-2 cells were similar in size to non-malignant mammary acini and were 
significantly smaller than those formed by cells treated with vehicle alone (Figure 2F).  
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T4-2 cells exhibit a basal level of activity of signaling kinases downstream of the 
EGFR (Figure 2G, lane 1) which is consistent with a response to the ongoing production 
of an EGFR ligand by these cells. The basal activities were significantly suppressed by 
addition of TAPI-2 (Figure 2G, lane 3) but the cells remained competent to respond to 
addition of exogenous EGF (Figure 2G, lane 4). Furthermore, TAPI-2 caused a dose-
dependent decrease in proliferation of T4-2 cells in 2D cultures, which was overcome by 
addition of exogenous EGF (Figure 2H). This compound was not cytotoxic at the 
concentration used, nor did it interfere with the ability of S1 cells to execute normal 
acinar morphogenesis in the presence of soluble EGF (data not shown). Thus, the 
proliferative block and concomitant reversion resulting from metalloproteinase inhibition 
appears to result, at least in part, from a defect in growth factor mobilization, suggesting 
that either an MMP or ADAM family member plays a crucial role in the regulation of 
EGFR signaling in this transition to growth factor autonomy. 
TACE/ADAM17 cleaves both AREG and TGFα in cultured mammary epithelial 
cells 
Several lines of genetic and biochemical evidence suggest that TACE/ADAM17 
is a key regulator of cleavage of both AREG and TGFα (Borrell-Pages et al., 2003; 
Gschwind et al., 2003; Sahin et al., 2004). TACE is expressed in both S1 and T4-2 cells 
(Figure 3A). To test whether TACE could cleave endogenously produced growth factors 
in mammary epithelial cells, we cloned and overexpressed the transmembrane precursors 
of Amphiregulin and TGFα in S1 cells. Acute stimulation of these cells with recombinant 
TACE was sufficient to mobilize the growth factors to activate receptor tyrosine kinase 
signaling (Figure 3B), a response not elicited in the vector control cells. Introduction of 
siRNAs against TACE significantly suppressed T4-2 cell proliferation compared to both 
GFP-transfected and random siRNA-transfected controls (Figure 3C). Thus it appears 
that TACE, and not another TAPI-2-sensitive protease, is the primary growth factor 
sheddase in T4-2 cells. 
AREG and TGFα are the key substrates of TACE in T4-2 cells  
In addition to shedding growth factors, TACE has been implicated in the shedding 
of several cell surface molecules, inhibition of which might also contribute to the 
observed reversion of the T4-2 cell phenotype. Characterized substrates of TACE include 
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TNFα (Black et al., 1997; Moss et al., 1997), L-Selectin and TNFRII (Peschon et al., 
1998), β-APP (Buxbaum et al., 1998), collagen XVII (Franzke et al., 2002), growth 
hormone receptor (Zhang et al., 2000), TrkA (Diaz-Rodriguez et al., 2002), ErbB4 (Rio 
et al., 2000) and GPIbα (Bergmeier et al., 2004). To test whether modulation of growth 
factor cleavage is the key role of TACE here, we generated soluble secreted mutants of 
both AREG and TGFα which lack both the transmembrane and cytosolic domains 
(Figure 4A). and sought to determine whether their overexpression might lead to a 
genetic rescue of the TAPI-2-imposed reversion.  
Each stably transfected T4-2 cell line was susceptible to reversion by EGFR 
inhibition (Figure 4B). Those cells which produced soluble growth factors were 
completely resistant to TAPI-2 (Figure 4B). Thus, despite the number of TACE 
substrates expressed by these cells, it is the suppression of growth factor mobilization 
which results in the reversion of the malignant phenotype.  
EGFR ligand bioavailability antagonizes inhibitor efficacy  
Small molecule inhibitors of the EGFR have thus far proven disappointing in 
phase III clinical trials. Like AG1478, Gefitinib (Iressa, ZD1839) and Erlotinib (Tarceva, 
OSI-774) are reversible anilinoquinazoline-derivatives. In two large trials of non-small 
cell lung cancer (NSCLC) patients, Chemotherapy with Gefitinib performed no better 
than chemotherapy alone in terms of survival (Giaccone et al., 2004; Herbst et al., 2004). 
Although Erlotinib did provide a statistically significant survival benefit in patients with 
advanced pancreatic adenocarcinoma, it is important to note that the median extension in 
progression-free survival was a mere six days, while the median increase in overall 
survival was 14 days (Moore, M.J. et al. Erlotinib improves survival when added to 
gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National 
Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Gastrointestinal 
Cancers Symposium (2005) Abstract 77). In a recent trial using Erlotinib as a single agent 
in NSCLC, median progression-free survival time was increased by almost two weeks in 
the treated population, while median overall survival was increased by two months 
(Shepherd et al., 2005). 
Despite the fact that T4-2 cells expressing soluble AREG or TGFα still formed 
small rounded colonies in the presence of the EGFR inhibitor, these colonies were 
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consistently larger than those formed by cells infected with either empty vector or with 
the membrane-tethered pro-forms of AREG and TGFα (Figure 4B). The difference was 
statistically significant (median cross-sectional area of AG1478-treated proAREG v 
AREG∆TM colonies, P < 0.0001; proTGFα v TGFα∆TM, P <0.05). We postulated that 
successful inhibition of the EGFR by anilinoquinazoline inhibitors might be a function of 
the availability of circulating ligand and tested this hypothesis in a quantitative fashion in 
T4-2 cells (Figure 4C). The malignant phenotype of T4-2 cells (typically cultured in the 
absence of EGF) may be reverted using AG1478. Increasing the amount of soluble EGF 
allowed the T4-2 cells to escape from the AG1478-imposed reversion (Figure 4C). 
Similar observations were made with both recombinant Amphiregulin and TGFα (data 
not shown). Thus it seems that there is a transition point of ligand concentration above 
which EGFR inhibitors lack efficacy. In the 3D culture assay, this transition occurred 
between 0.1 and 1 ng/ml. Reported levels of EGF and TGFα (both circulating and in 
tumor and tissue homogenates) are within or exceed this range (Messa et al., 1998; Reeka 
et al., 1998; Sotnikova et al., 2001).  
TACE and TGFα predict poor prognosis in human breast cancer patients  
Having thus established that TACE-dependent growth factor shedding plays a role 
that is both critically important and therapeutically tractable in this model of breast 
cancer progression, we sought to determine the extent to which these factors play a role 
in human breast cancer. We interrogated a comprehensive microarray dataset of 295 
primary human breast tumors which was prepared by Marc van de Vijver and colleagues, 
who used it to identify gene expression signatures predictive of outcome. The detailed 
clinical characteristics of these tumors have been reported (van de Vijver et al., 2002). 
Briefly, all were either stage I or II and less than 5 cm diameter at excision, and derived 
from 295 consecutively treated patients less than 53 years old. Approximately three 
quarters of the tumors were ERα positive, and half were associated with positive lymph 
nodes. The median time for which follow-up information is available is 6.7 years (range 
0.05 – 18.3 years).  
Our analysis of this publicly available dataset revealed a statistically significant 
positive correlation between expression levels of TGFα and TACE (Table 1, P < 0.001). 
EGFR expression also tended to correlate with both TGFα and TACE, although not quite 
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reaching the level of statistical significance (P = 0.053 and P = 0.061, respectively). 
Interestingly, Amphiregulin expression in this patient population was inversely correlated 
with expression of EGFR and TGFα (P < 0.05 and P < 0.001, respectively). 
Amphiregulin and TACE levels tended to be anti-correlated, although not quite reaching 
statistical significance (P = 0.053). While these three markers were co-expressed in our 
progression model, these data suggest that TACE and TGFα may be the more important 
protease/growth factor pair for EGFR activation in human breast tumors. Tumors positive 
for TGFα, ADAM17 and EGFR tended to be ERα negative (P < 0.0001, P < 0.005, P < 
0.0001 respectively). Conversely, ERα positive tumors tended to have higher levels of 
Amphiregulin (P < 0.0001). 
To analyze the contribution of AREG, TGFα, and TACE expression to survival, 
tumors were divided in quartiles by expression level of each marker and survival curves 
were computed for the upper and lower quartiles (74 samples each) and the interquartile 
range (147 samples). High levels of TACE expression were associated with a poor 
survival (Figure 5A, P < 0.05, high v. low expression). Tumors with the highest levels of 
TGFα expression also tended to have a poorer outcome, although statistically this was 
borderline (Figure 5B, P < 0.06). Tumors which express high levels of Amphiregulin had 
a significantly better outcome than tumors expressing lower levels (Figure 5C, P < 0.001) 
as expected from the high correlation between Amphiregulin and ERα expression levels, 
positivity for the latter being a strong predictor of survival (Figure 5D, P < 0.001). 
These data illuminate the necessary steps, at a molecular level, by which tumor 
cells may become independent of extrinsic proliferative signals and suggest that ADAM 
family members may prove important additional therapeutic targets in EGFR-dependent 
malignancies of the breast and other tissues. 
Discussion 
In this study, we show that activation of EGFR signaling in the T4-2 cells of the 
HMT3522 breast cancer progression series is driven by a TACE-dependent growth factor 
autocrine loop not present in the non-malignant S1 cells. Inhibition of TACE attenuated 
the growth of T4-2 cells in 3D ECM culture and reverted their morphology to 
approximate that of non-malignant cells. This reversion was overcome by overexpression 
of soluble “pre-cleaved” mutants of either AREG or TGFα but not by pro-AREG or pro-
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TGFα, definitively demonstrating the importance of growth factor precursor cleavage for 
ErbB function. We further show that expression of TACE and TGFα is highly correlated 
in human breast cancer samples and is predictive of poor prognosis. Lastly, we 
demonstrate that ligand bioavailability, which can be modulated by TACE inhibition, is 
an important determinant of EGFR inhibitor efficacy. 
Despite the development of potent, specific EGFR inhibitors, EGFR-dependent 
tumors of several tissues remain a substantial clinical problem. Some patients who do 
respond to therapy have tumors bearing EGFR mutations (Lynch et al., 2004; Paez et al., 
2004), but this explained only a proportion of responses in these studies, and the 
association has not been reproduced in another large study (Tsao et al., 2005). Our data 
demonstrate that the utility of an EGFR inhibitor may be a function of the abundance of 
ligand and that low picomolar levels of these growth factors can overcome the efficacy of 
the inhibitor. If so, physiological levels of EGFR ligands may antagonize the action of 
EGFR inhibitors in vivo. Among the small proportion of patients whose tumors respond 
to small molecule EGFR inhibitors, there is frequent and pronounced adverse systemic 
reactions to the drug, including skin rash and diarrhea. Intriguingly, these systemic 
responses predict response to Gefitinib (Chiu et al., 2005; Mohamed et al., 2005; Perez-
Soler et al., 2004). The fact that systemic toxicity predicts response is consistent with the 
hypothesis that circulating and locally produced EGFR ligands antagonize Gefitinib 
efficacy in both the tumor and in other organs: Those patients with circulating ligands 
above a threshold would experience neither skin rashes nor tumor regression in response 
to Gefitinib. This hypothesis is supported by our demonstration in 3D cultures that EGFR 
inhibitor efficacy is critically dependent on the bioavailability of EGFR ligands, and that 
ligand concentrations within the normal circulating range (Messa et al., 1998; Reeka et 
al., 1998; Sotnikova et al., 2001) confer resistance to the inhibitor. Interestingly, 
Amphiregulin overexpression predicts non-responsiveness to Gefitinib in ERRB2-
positive non-small cell lung cancer tumors (Kakiuchi et al., 2004). Undoubtedly in some 
cases Gefitinib resistance is acquired in a cell-autonomous fashion by tumor cells, by loss 
of PTEN (She et al., 2003), by acquisition of mutation in EGFR (Pao et al., 2005), or 
perhaps by switching dependence to other ErbB family members. However, it is difficult 
to understand how such changes within the primary tumor could ameliorate the systemic 
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toxicity. Thus we believe that systemic resistance to EGFR inhibitors, resulting from an 
excess of circulating EGFR ligands, may be an important predictive determinant for 
anilinoquinazoline efficacy and that reduction of the levels of circulating growth factors 
by inhibiting growth factor shedding may improve the efficacy of these compounds. 
The demonstration of an absolute requirement for an ADAM-like proteolytic 
activity for proliferation in a physiologically relevant model of human breast cancer 
progression suggests another avenue to be explored therapeutically. MMPs and ADAMs 
have been studied intensively and many small molecule inhibitors have been 
characterized in both cell culture and animal models, primarily to inhibit MMP-
dependent tumor cell invasion. Despite the relative success of pre-clinical studies, the 
results of many clinical trials of MMP inhibitors in cancer have been disappointing, 
perhaps due to what retrospectively appears to be flawed design of the Phase III studies 
(Coussens et al., 2002). It has become clear that metalloproteinases play more complex 
and diverse roles in tumor progression (Egeblad and Werb, 2002) than was appreciated 
during the design of these earlier clinical studies. It remains possible that these 
compounds may prove efficacious in selected subsets of patients, one such cohort being 
those who depend on TACE-dependent autocrine stimulation of EGFR/ErbB2. Specific 
and orally active TACE inhibitors have been developed by Roche (Beck et al., 2002) and 
Wyeth (Zhang et al., 2004) for treatment of arthritis; our data suggest that their efficacy 
should be evaluated in a pre-clinical models of EGFR ligand-dependent tumorigenesis. 
Our data delineate a mechanism by which breast epithelial cells may escape 
dependence on extrinsic proliferative signals, a transition necessary in the evolution of all 
cancers. The essential role of TACE in this phenotype, and the demonstration that 
inhibition of this protease blocks EGFR signaling and reverts the malignant phenotype 
suggests that interruption of such an autocrine loop might prove an effective therapy for 
tumors dependent on EGFR ligand expression, alone or in combination with existing 
EGFR inhibitors. 
Experimental Procedures 
Cell culture All reagents were purchased from SIGMA (St. Louis, MO) except 
where otherwise noted. HMT3522 cells were cultivated on 2D and 3D substrata in H14 
medium, a 50:50 mix of DMEM/F12 (UCSF Cell culture Facility, San Francisco, CA) 
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supplemented with 5 µg/ml prolactin, 250 ng/ml insulin, 1.4 x 10-6 M hydrocortisone, 10-
10 M β-estradiol, 2.6 ng/ml sodium selenite and 10 µg/ml transferrin. S1 cells were 
additionally supplemented with 10 ng/ml EGF. In various experiments, cells were 
supplemented with AREG, TACE, TGFα. In all cases, AREG and TGFα were used at 
the same molar concentration as EGF (860 pM). 
For 3D lrECM culture, T4-2 cells were seeded at 21000 cells per cm2 on top of 
Matrigel, overlaid with H14 medium containing 5% Matrigel (BD Biosciences, San Jose, 
CA), and treated with 80 nM AG1478, 20 µM TAPI-2 or the relevant vehicle controls. 
Amphotropic retroviruses were generated by transfection (Lipofectamine; 
Invitrogen, Carlsbad, CA) of the Phoenix packaging cell line (a gift of Dr. Gary Nolan, 
Stanford) with pBM-IRES-Puro or derivatives containing the AREG or TGFα open 
reading frames. Two million phoenix cells per 6 cm dish were plated the day prior to 
transfection and transfected with 2 µg of the appropriate retroviral construct. Retrovirus-
containing culture medium was harvested after 48 hrs, supplemented with polybrene to 
5µg/ml and added to HMT3522 cells at 30-50% confluence. Pools of stable infectants 
were selected in 1 µg/ml puromycin. 
SilencerTM siRNAs against TACE (Ambion, Austin, TX) were co-transfected with 
pEGFP-C1 (BD Biosciences). T4-2 cells were trypsinized post-transfection and plated at 
low density. Proliferation was assessed by counting the transfected (green) cells per 
colony after four days. Random siRNA sequence was used as a negative control. 
Indirect immunofluorescence. Colonies were solubilized from matrigel culture 
by shaking in PBS/0.05M EDTA on ice for 30 mins, fixed in 4% paraformaldehyde, 
permeabilized, stained with anti-α6-integrin (Chemicon, Temecula, CA) and 
counterstained with DAPI. 
Western blotting. Cells were lysed in 50 mM Tris.HCl pH 7.5, 150 mM NaCl, 
0.5% NP40 supplemented with protease and phosphatase inhibitors (Calbiochem, San 
Diego, CA) and clarified by centrifugation. 50 µg of each sample was fractionated by 
SDS-PAGE, transferred to nitrocellulose membranes and probed with antibodies against 
the following proteins: phospho-MAPK, Total MAPK, phospho-p70S6-Kinase, (Cell 
Signaling Technology, MA). E-cadherin (BD Biosciences, CA) was used as a loading 
Kenny & Bissell; Targeting TACE-dependent growth factor shedding in breast cancer 
 13 
control. Blots were developed using Supersignal West Femto (Pierce, Rockland, IL). 
Images were captured using a FluorChem 8900 imager (Alpha Innotech, San Leandro, 
CA). 
Cloning of pro-AREG and pro-TGFα. The open reading frames of these genes 
were amplified by PCR from T4-2 cDNA. Amplification products were cloned, sequence 
verified, and subcloned into the retroviral expression vector, pBM-IRES-Puro (Garton et 
al., 2002). The primers used were: AREG: 5’-GACCTCAATGACACCTACTCTGG-3’, 
5’-GAAATATTCTTGCTGACATTTGC-3’ ; TGFα: 5’-
ATGGTCCCCTCGGCTGGACAGCTC-3’, 5’-
TCATAGATCTTCTTCTGATATAAGCTTTTGTTCGACCACTGTTTCTGAGTGGC-
3’. The ∆TM mutants of AREG and TGFα were generated from the using the pBM-
IRES-puro specific primer 5’-TGGAAAGGACCTTACACAGTCC-3’ and either 5’-
AAAAGGATCCTCATTTTGATAAACTACTGTCAATC-3’ (AREG∆TM) or 5’-
AAAAGGATCCTCAGGCCTGCTTCTTCTGGCTGGC-3’ (TGFα∆TM) and cloned 
into pBM-IRES-Puro. 
Proliferation assays. HMT3522 cells were seeded in 96 well plates and treated 
(in triplicate) as described in the figure legends. To determine relative growth, 0.1 
volumes of WST cell proliferation analysis reagent (Roche, Indianapolis, IN) was added 
to the medium and its formazan metabolite was measured by absorbance at 460 nm.  
RTPCR. DNase-treated total RNA was isolated using the RNEasy kit (Qiagen, 
Valencia, CA). 5 µg of total RNA in a final volume of 40 µl was used for oligo dT 
primed cDNA synthesis (First Strand cDNA synthesis kit, Invitrogen, Carlsbad, CA). 1 
µl of cDNA was added to a 60 µl PCR reaction. 15 µl aliquots were withdrawn after 25, 
30 and 35 cycles and analyzed by agarose gel electrophoresis. Primers used were as 
follows: AREG: 5’-GACCTCAATGACACCTACTCTGG-3’, 5’-
GAAATATTCTTGCTGACATTTGC-3’ ; GAPDH: 5’-
CCCCTGGCCAAGGTCATCCATGAC-3’, 5’-
CATACCAGGAAATGAGCTTGACAAAG-3’ ; TACE: 5’-
CAGCACAGCTGCCAAGTCATT-3’, 5’-CCAGCATCTGCTAAGTCACTTCC-3’; 
TGFα: 5’-CACACTCAGTTCTGCTTCCA-3’, 4’-
TCAGACCACTGTTTCTGAGTGGC-3’. 
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Statistical Analyses. All data analysis was performed using Graphpad Prism. Bar 
graphs represent mean ± standard error of mean. Significance was determined using 
ANOVA. In scatter plots, the horizontal bar represents the median of each dataset. 
Significance was determined using Kruskal-Wallis test (with Dunn’s Test to correct for 
multiple comparisons). 
 A database consisting of the microarray profiles of 295 human breast tumors with 
the associated clinical data (van de Vijver et al., 2002) was obtained from Rosetta 
Inpharmatics. Pearson’s correlation coefficient was used to determine whether 
statistically significant associations existed between the relative expression levels of each 
of the markers. For survival analysis, patients were stratified into quartiles for expression 
of each marker, and survival curves computed using the method of Kaplan and Meier. 
Statistical significance was determined using the log-rank test.  
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Table 1 Pearson’s correlation analysis of markers in 295 primary human breast tumors 
 
 AREG   ERα   TGFα   ADAM17   EGFR   
 r p r p r p r p R p 
ERα 0.4177 <0.0001             
TGFα -0.2155 0.0002 -0.3851 <0.0001          
ADAM17 -0.1126 0.0534 -0.1774 0.0022 0.1917 0.0009       
EGFR -0.1416 0.0150 -0.2755 <0.0001 0.1127 0.0532 0.1093 0.0609    
ERBB2 0.1897 0.0011 -0.0943 0.1062 -0.1027 0.0783 -0.0340 0.5609 -0.0557 0.3407 
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FIGURE LEGENDS 
 
Figure 1. Amphiregulin and TGFα are upregulated in T4-2 cells and can substitute for 
EGF to promote proliferation of S1 cells 
A: RT-PCR analysis shows that both Amphiregulin and TGFα are transcriptionally 
upregulated in T4-2 relative to S1 cells.  
B: S1 cells cultured for six days in the absence of EGF do not proliferate.  
C-E: S1 cells proliferate in the presence of equimolar (860 pM) of each EGFR ligand.  
F: S1 cell proliferation in the presence of each ligand is significantly different from 
control. 
G: RT-PCR analysis shows that both Amphiregulin and TGFα are upregulated in non-
malignant S2 cells. 
 
Figure 2. Inhibition of sheddase activity reverts the malignant phenotype of T4-2 cells by 
suppressing mobilization of growth factors and downregulating EGFR pathway activity 
A: T4-2 cells grown in 3D lrECM culture form continuously proliferating, disorganized, 
and apolar colonies.  
B: T4-2 cells treated with EGFR inhibitor (80 nM AG1478) undergo morphological 
reversion, forming small, smooth, spherical, growth-arrested colonies.  
C: T4-2 cells treated with a broad-spectrum MMP/ADAM inhibitor (20 µM TAPI-2) 
undergo a morphological reversion similar to that of EGFR inhibitor-treated cells. Bar = 
100 µm.  
D: α6-integrin staining of T4-2 cells indicates absence of tissue polarity.  
E: α6-integrin staining of T4-2 cells shows restoration of tissue polarity in TAPI-2 
treated cells. Bar = 10 µm.  
F: Analysis of cross-sectional area of T4-2 cells treated with vehicle, AG1478 or TAPI-2 
for four days. Both AG1478 and TAPI-2 treated colonies were significantly different 
from controls (p < 0.001).  
G: TAPI-2 treatment (24 hours) reduces the basal activity of kinases downstream of 
EGFR, but cells remain competent to respond to exogenous EGF (860 pM, 5 minute 
stimulation).  
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H: TAPI-2 treatment results in a dose-dependent reduction in T4-2 cell proliferation that 
is completely overcome by addition of soluble EGF.  
 
Figure 3. TACE/ADAM17 cleaves both Amphiregulin and TGFα, and promotes T4-2 
cell proliferation 
A: RTPCR analysis showing TACE expression in both S1 and T4-2 cells.  
B: Stimulation with recombinant TACE (5 mins) activated EGFR signaling in S1 cells 
overexpressing full-length Amphiregulin or TGFα, but not in vector-transfected cells.  
C: Suppression of TACE expression reduced T4-2 cell proliferation. 
 
Figure 4. TAPI-2 induced reversion of T4-2 cells is a direct result of inhibition of growth 
factor ectodomain shedding  
A: Schematic representation of full-length and deletion mutants of Amphiregulin and 
TGFα. ∆TM mutants lack both the transmembrane and cytoplasmic domain and are thus 
secreted without requiring TACE activity.  
B: T4-2 cells overexpressing both full-length and deletion growth factor constructs are 
susceptible to reversion induced by the EGFR inhibitor, but those cells expressing either 
soluble Amphiregulin or TGFα escape the TAPI-2-imposed reversion. Bar = 100 µm.  
C: Reversion of T4-2 cells by EGFR inhibition is overcome by the presence of picomolar 
amounts of EGFR ligand. Cells were cultured for four days in 80 nM AG1478 and 
various amounts of EGF. Above a threshold EGF concentration between 0.1 - 1 ng/ml 
(8.6 - 86 pM), the EGFR inhibitor can no longer revert the malignant phenotype. Bar = 
100 µm. 
 
Figure 5. Kaplan-Meier survival analysis of 295 human breast tumors stratified by 
marker expression level 
High levels of (A) TACE and (B) TGFα predict poor survival. High levels of (C) 
Amphiregulin or (D) ERα are predictive of survival. P values represent the log-rank 
comparison between the upper and lower quartiles of marker expression. 
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